news
Silo Pharma initiates pre-IND package for ketamine to treat fibromyalgia
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
List view / Grid view
Fibromyalgia
article
Fibromyalgia pathogenesis provides drug target clues
Fibromyalgia (FM) has been described as a condition of heightened generalised sensitisation to sensory input presenting as a complex of symptoms dominated by chronic widespread pain characterised by hyperalgesia and allodynia. A range of co-morbidities of variable intensity, such as fatigue, sleep disturbance, cognitive impairment, anxiety and depression, are often…
